Loading…
Loading…
Smouldering myeloma meets laboratory criteria for myeloma but has no organ damage or myeloma-defining events.
Quick Answer
Smouldering myeloma meets laboratory criteria for myeloma but has no organ damage or myeloma-defining events. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates smouldering multiple myeloma at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
Smouldering myeloma is an intermediate precursor between MGUS and active myeloma. Some patients remain stable for years, while others progress quickly. Risk stratification uses M-protein level, marrow plasma cells, free light chain ratio and imaging.
Criteria require an M-protein of 30 g/L or more or marrow plasma cells of 10% or more, without myeloma-defining events. Whole-body imaging and risk stratification are recommended.
Most patients are monitored closely. Selected high-risk patients may be offered treatment or a clinical trial. Treatment begins when myeloma-defining events or progressive organ damage appear.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven prevention. Close monitoring and prompt treatment at progression are the main strategies.
Red flags — seek urgent care
Active myeloma has organ damage or myeloma-defining events. Smouldering myeloma has laboratory abnormalities but no such events and is usually observed.
Monitoring is usually more frequent than for MGUS, often every few months, and depends on risk and stability.
Selected high-risk patients may be offered treatment or trials, but routine early treatment is not standard for all patients. The balance of benefit and toxicity is discussed individually.
High-risk features include a high M-protein, high marrow plasma cell percentage, abnormal free light chain ratio and certain genetic findings. Risk models guide monitoring and trial eligibility.
Whole-body imaging detects bone or extramedullary disease that would reclassify the condition as active myeloma.
Some patients remain stable or improve, but progression can occur. Regular monitoring is needed.
New bone pain, fatigue, breathlessness, kidney problems, confusion or recurrent infections should be reviewed promptly.
Transplant is used for active myeloma, not for smouldering disease outside clinical trials.
Specialist assessment for abnormal blood counts, anaemia, low platelets, bleeding, clotting and suspected blood disorders.
Diagnosis and treatment of multiple myeloma, MGUS, smouldering myeloma and AL amyloidosis.
Diagnostic bone marrow sampling for cytopenias, suspected blood cancer and treatment monitoring.
Multiple myeloma is a cancer of plasma cells that causes bone disease, anaemia, kidney problems and immune suppression.
MGUS is a common precursor plasma cell condition with a small monoclonal protein and no organ damage.
AL amyloidosis is a plasma cell disorder in which abnormal light chains deposit in organs and impair their function.
Haematology
Multiple Myeloma: A Practical Guide for Patients and Families
Myeloma is a treatable plasma cell cancer. Understand the tests, treatment options, transplant and supportive care.
Haematology
MGUS: What It Means and How Often to Monitor
Monoclonal gammopathy of undetermined significance is a common precursor condition. Most people with MGUS never develop myeloma.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.